Please use this identifier to cite or link to this item: https://doi.org/10.1007/s11095-008-9611-6
Title: In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy
Authors: Zhang, Z. 
Lee, S.H.
Gan, C.W.
Feng, S.-S. 
Keywords: Chemotherapeutic engineering
Controlled release
Nanomedicine
Nanopharmaceutical engineering
Paclitaxel
Issue Date: Aug-2008
Source: Zhang, Z.,Lee, S.H.,Gan, C.W.,Feng, S.-S. (2008-08). In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharmaceutical Research 25 (8) : 1925-1935. ScholarBank@NUS Repository. https://doi.org/10.1007/s11095-008-9611-6
Abstract: Purpose. The aim of this work was to evaluate in vivo poly(lactide)-d- α-tocopheryl polyethylene glycol 1,000 succinate nanoparticles (PLA-TPGS NPs) for controlled and sustained small molecule drug chemotherapy. Methods. The drug-loaded PLA-TPGS NPs were prepared by the dialysis method. Particle size, surface morphology and surface chemistry, in vitro drug release and cellular uptake of NPs were characterized. In vitro and in vivo therapeutic effects of the nanoparticle formulation were evaluated in comparison with Taxol®. Results. The PLA-TPGS NP formulation exhibited significant advantages in in vivo pharmacokinetics and xenograft tumor model versus the PLGA NP formulation and the pristine drug. Compared with Taxol®, the PLA-TPGS NP formulation achieved 27.4-fold longer half-life in circulation, 1.6-fold larger area-under-the-curve (AUC) with no portion located above the maximum tolerance concentration level. For the first time in the literature, one shot for 240 h chemotherapy was achieved in comparison with only 22 h chemotherapy for Taxol® at the same 10 mg/kg paclitaxel dose. Xenograft tumor model further confirmed the advantages of the NP formulation versus Taxol®. Conclusions. The PLA-TPGS NP formulation can realize a way of controlled and sustained drug release for more than 10 days, which relieves one of the two major concerns on cancer nanotechnology, i.e. feasibility. © 2008 Springer Science+Business Media, LLC.
Source Title: Pharmaceutical Research
URI: http://scholarbank.nus.edu.sg/handle/10635/64085
ISSN: 07248741
DOI: 10.1007/s11095-008-9611-6
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

88
checked on Dec 12, 2017

Page view(s)

45
checked on Dec 7, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.